Chottawornsak N, et al. - Researchers tested the safety and effectiveness of ketoconazole (KTZ) cream, a topical antifungal with anti-inflammatory and antiandrogenic actions, in mild adult female acne (AFA) by performing a randomized, double-blind, placebo-controlled trial using KTZ 2% and placebo cream for 10 weeks twice a day. The research was participated by 41 candidates. Investigators found that the proportion of candidates with baseline acne improvement and the KTZ group success rate was significantly higher than the placebo group. They concluded that in improving AFA with an excellent safety profile, the KTZ monotherapy had a plausible impact. It should be considered a viable alternative for treating mild AFA. Dryness and itching were the most common adverse events.